The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Open accessAbstract
BACKGROUND: Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is characterized by a gene-expression profile similar to that of BCR-ABL1-positive ALL, alterations of lymphoid transcription factor genes, and a poor outcome. The frequency and spectrum of genetic alterations in Ph-like ALL and its responsiveness to tyrosine kinase inhibition are undefined, especially in adolescents and adults. METHODS: We performed genomic profiling of 1725 patients with precursor B-cell ALL and detailed genomic analysis of 154 patients with Ph-like ALL. We examined the functional effects of fusion proteins and the efficacy of tyrosine kinase inhibitors in mouse pre-B cells and xenografts of human Ph-like ALL. RESULTS: Ph-like ALL increased in frequency from 10% among children with standard-risk ALL to 27% among young adults with ALL and was associated with a poor outcome. Kinase-activating alterations were identified in 91% of patients with Ph-like ALL; rearrangements involving ABL1, ABL2, CRLF2, CSF1R, EPOR, JAK2, NTRK3, PDGFRB, PTK2B, TSLP, or TYK2 and sequence mutations involving FLT3, IL7R, or SH2B3 were most common. Expression of ABL1, ABL2, CSF1R, JAK2, and PDGFRB fusions resulted in cytokine-independent proliferation and activation of phosphorylated STAT5. Cell lines and human leukemic cells expressing ABL1, ABL2, CSF1R, and PDGFRB fusions were sensitive in vitro to dasatinib, EPOR and JAK2 rearrangements were sensitive to ruxolitinib, and the ETV6-NTRK3 fusion was sensitive to crizotinib. CONCLUSIONS: Ph-like ALL was found to be characterized by a range of genomic alterations that activate a limited number of signaling pathways, all of which may be amenable to inhibition with approved tyrosine kinase inhibitors. Trials identifying Ph-like ALL are needed to assess whether adding tyrosine kinase inhibitors to current therapy will improve the survival of patients with this type of leukemia. (Funded by the American Lebanese Syrian Associated Charities and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
Mullighan, C. G., Su, X., Zhang, J., Radtke, I., Phillips, L. A. A., Miller, C. B., Ma, J., Liu, W., Cheng, C., Schulman, B. A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808253 · Cited by 1,422
Self-citationInaba, H., Greaves, M., & Mullighan, C. G. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62187-4 · Cited by 1,074
Self-citationBCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
Mullighan, C. G., Miller, C. B., Radtke, I., Phillips, L. A., Dalton, J., Ma, J., White, D., Hughes, T. P., Le Beau, M. M., Pui, C.-H., et al. (2008) · Nature · doi:10.1038/nature06866 · Cited by 1,072
Self-citationDen Boer, M. L., van Slegtenhorst, M., De Menezes, R. X., Cheok, M. H., Buijs-Gladdines, J. G., Peters, S. T., Van Zutven, L. J., Beverloo, H. B., Van der Spek, P. J., Escherich, G., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70339-5 · Cited by 930
Self-citationExpression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma
Tognon, C., Knezevich, S. R., Huntsman, D., Roskelley, C. D., Melnyk, N., Mathers, J. A., Becker, L., Carneiro, F., MacPherson, N., Horsman, D., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00180-0 · Cited by 911
A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma
Knezevich, S. R., McFadden, D. E., Tao, W., Lim, J. F., & Sorensen, P. H. B. (1998) · Nature Genetics · doi:10.1038/ng0298-184 · Cited by 800
A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia
Lacronique, V., Boureux, A., Della Valle, V., Poirel, H., Quang, C. T., Mauchauffé, M., Berthou, C., Lessard, M., Berger, R., Ghysdael, J., et al. (1997) · Science · doi:10.1126/science.278.5341.1309 · Cited by 791
Roberts, K. G., Morin, R. D., Zhang, J., Hirst, M., Zhao, Y., Su, X., Chen, S.-C., Payne-Turner, D., Churchman, M. L., Harvey, R. C., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.005 · Cited by 714
Self-citationSchultz, K. R., Bowman, W. P., Aledo, A., Slayton, W. B., Sather, H., Devidas, M., Wang, C., Davies, S. M., Gaynon, P. S., Trigg, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.2514 · Cited by 701
Self-citationRearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia
Mullighan, C. G., Collins-Underwood, J. R., Phillips, L. A. A., Loudin, M. G., Liu, W., Zhang, J., Ma, J., Coustan-Smith, E., Harvey, R. C., Willman, C. L., et al. (2009) · Nature Genetics · doi:10.1038/ng.469 · Cited by 623
Self-citationHarvey, R. C., Mullighan, C. G., Chen, I.-M., Wharton, W., Mikhail, F. M., Carroll, A. J., Kang, H., Liu, W., Dobbin, K. K., Smith, M. A., et al. (2010) · Blood · doi:10.1182/blood-2009-09-245944 · Cited by 574
Self-citationRussell, L. J., Capasso, M., Vater, I., Akasaka, T., Bernard, O. A., Calasanz, M. J., Chandrasekaran, T., Chapiro, E., Gesk, S., Griffiths, M., et al. (2009) · Blood · doi:10.1182/blood-2009-03-208397 · Cited by 498
Role of ABL family kinases in cancer: from leukaemia to solid tumours
Greuber, E. K., Smith-Pearson, P., Wang, J., & Pendergast, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3563 · Cited by 432
Knezevich, S. R., Garnett, M. J., Pysher, T. J., Beckwith, J. B., Grundy, P. E., & Sorensen, P. H. B. (1998) · PubMed · Cited by 412
A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia
Shah, S., Schrader, K. A., Waanders, E., Timms, A. E., Vijai, J., Miething, C., Wechsler, J., Yang, J., Hayes, J., Klein, R. J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2754 · Cited by 327
Self-citationTargeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
Maude, S. L., Tasian, S. K., Vincent, T., Hall, J. W., Sheen, C., Roberts, K. G., Seif, A. E., Barrett, D. M., Chen, I.-M., Collins, J. R., et al. (2012) · Blood · doi:10.1182/blood-2012-03-415448 · Cited by 289
Self-citationvan der Veer, A., Waanders, E., Pieters, R., Willemse, M. E., Van Reijmersdal, S. V., Russell, L. J., Harrison, C. J., Evans, W. E., van der Velden, V. H. J., Hoogerbrugge, P. M., et al. (2013) · Blood · doi:10.1182/blood-2012-10-462358 · Cited by 289
Self-citationMacrophage colony-stimulating factor receptor c-fms is a novel target of imatinib
Dewar, A. L., Cambareri, A. C., Zannettino, A. C. W., Miller, B. L., Doherty, K. V., Hughes, T. P., & Lyons, A. B. (2005) · Blood · doi:10.1182/blood-2004-10-3967 · Cited by 284
Self-citationTasian, S. K., Doral, M. Y., Borowitz, M. J., Wood, B. L., Chen, I.-M., Harvey, R. C., Gastier-Foster, J. M., Willman, C. L., Hunger, S. P., Mullighan, C. G., et al. (2012) · Blood · doi:10.1182/blood-2011-12-389932 · Cited by 240
Self-citationWeston, B. W., Hayden, M. A., Roberts, K. G., Bowyer, S., Hsu, J., Fedoriw, G., Rao, K. W., & Mullighan, C. G. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.6770 · Cited by 213
Self-citationWilliams, R. T., Roussel, M. F., & Sherr, C. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602030103 · Cited by 193
Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia
Williams, R. T., den Besten, W., & Sherr, C. J. (2007) · Genes & Development · doi:10.1101/gad.1588607 · Cited by 180
Loh, M. L., Zhang, J., Harvey, R. C., Roberts, K., Payne-Turner, D., Kang, H., Wu, G., Chen, X., Becksfort, J., Edmonson, M., et al. (2013) · Blood · doi:10.1182/blood-2012-04-422691 · Cited by 177
Self-citationLengline, E., Beldjord, K., Dombret, H., Soulier, J., Boissel, N., & Clappier, E. (2013) · Haematologica · doi:10.3324/haematol.2013.095372 · Cited by 172
Taipale, M., Krykbaeva, I., Whitesell, L. J., Santagata, S., Zhang, J., Liu, Q., Gray, N. S., & Lindquist, S. L. (2013) · Nature Biotechnology · doi:10.1038/nbt.2620 · Cited by 128
Self-citationAdolescents and Young Adults with Acute Lymphoblastic Leukemia
Stock, W. (2010) · Hematology · doi:10.1182/asheducation-2010.1.21 · Cited by 124
Self-citationGenomic Characterization of Childhood Acute Lymphoblastic Leukemia
Mullighan, C. G. (2013) · Seminars in Hematology · doi:10.1053/j.seminhematol.2013.10.001 · Cited by 123
Self-citationPoitras, J. L., Cin, P. D., Aster, J. C., DeAngelo, D. J., & Morton, C. C. (2008) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20585 · Cited by 65
Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia
Ernst, T., Score, J., Deininger, M. W., Hidalgo-Curtis, C., Lackie, P. M., Ershler, W. B., Goldman, J. M., Cross, N. C. P., & Grand, F. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08457.x · Cited by 46
Soler, G., Radford‐Weiss, I., Abdelali, R. B., Mahlaoui, N., Ponceau, J. F., Macintyre, E. A., Vekemans, M. J. J., Bernard, O., & Romana, S. P. (2007) · Leukemia · doi:10.1038/sj.leu.2405033 · Cited by 37
Cited by
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Self-citationAcute Lymphoblastic Leukemia in Children
Hunger, S. P., & Mullighan, C. G. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1400972 · Cited by 2,204
Self-citationStandards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
Li, M. M., Datto, M., Duncavage, E. J., Kulkarni, S., Lindeman, N. I., Roy, S., Tsimberidou, A. M., Vnencak-Jones, C. L., Wolff, D. J., Younes, A., et al. (2017) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.10.002 · Cited by 2,030
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
Terwilliger, T., & Abdul-Hay, M. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.53 · Cited by 1,288
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
Pui, C.-H., Yang, J. J., Hunger, S. P., Pieters, R., Schrappe, M., Biondi, A., Vora, A., Baruchel, A., Silverman, L. B., Schmiegelow, K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.1636 · Cited by 1,007
Self-citation
Metadata
- Authors
- Roberts, K. G., Li, Y., Payne-Turner, D., Harvey, R. C., Yang, Y.-L., Pei, D., McCastlain, K., Ding, L., Lu, C., Song, G., Ma, J., Becksfort, J., Rusch, M., Chen, S.-C., Easton, J., Cheng, J., Boggs, K., Santiago-Morales, N., Iacobucci, I., Fulton, R. S., Wen, J., Valentine, M., Cheng, C., Paugh, S. W., Devidas, M., Chen, I.-M., Reshmi, S., Smith, A., Hedlund, E., Gupta, P., Nagahawatte, P., Wu, G., Chen, X., Yergeau, D., Vadodaria, B., Mulder, H., Winick, N. J., Larsen, E. C., Carroll, W. L., Heerema, N. A., Carroll, A. J., Grayson, G., Tasian, S. K., Moore, A. S., Keller, F., Frei-Jones, M., Whitlock, J. A., Raetz, E. A., White, D. L., Hughes, T. P., Guidry Auvil, J. M., Smith, M. A., Marcucci, G., Bloomfield, C. D., Mrózek, K., Kohlschmidt, J., Stock, W., Kornblau, S. M., Konopleva, M., Paietta, E., Pui, C.-H., Jeha, S., Relling, M. V., Evans, W. E., Gerhard, D. S., Gastier-Foster, J. M., Mardis, E., Wilson, R. K., Loh, M. L., Downing, J. R., Hunger, S. P., Willman, C. L., Zhang, J., & Mullighan, C. G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-09-11
- Volume
- 371
- Issue
- 11
- Pages
- 1005-1015
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2148202982
- Cited by
- 1,377
- References
- 34
- FWCI
- 121.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.